Market Overview

UPDATE: Wedbush Downgrades Illumina to Neutral on Risk/Reward

Related ILMN
Is Illumina Worth Adding To Your Portfolio?
Mid-Day Market Update: U.S. Stocks Edge Higher; G-III Apparel Shares Jump On Upbeat Results
Making Money With Charles Payne: 09/26/14 (Fox Business)

Wedbush reduced its rating on Illumina (NASDAQ: ILMN) from Outperform to Neutral and reiterated its $52 price target.

Wedbush noted, "We have spoken with several typical sequencing customers recently that are either putting off or second guessing HiSeq purchases because of the attractive price point of ILMN's own sequencing service. In addition, for the first time, we are hearing about instances of used HiSeq 2000's for sale on the secondary market at steep discounts. On a positive note, near-term project pipelines appear robust and, despite continued MiSeq teething pains, feedback remains largely positive to date, with plans for greater utilization by core labs in 2013."

Illumina closed at $55.55 on Thursday.

Latest Ratings for ILMN

DateFirmActionFromTo
Oct 2014Stifel NicolausMaintainsBuy
Oct 2014Credit Suisse
Oct 2014Cantor Fitzgerald

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ILMN)

Around the Web, We're Loving...

Get Benzinga's Newsletters